Skip to main content
Top
Published in: Medical Oncology 3/2003

01-09-2003 | Original Article

Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma

Association with severe myelotoxicity

Authors: Dr. Gil Bar-Sela, Diana Gaitini, Mariana Steiner, Nissim Haim

Published in: Medical Oncology | Issue 3/2003

Login to get access
Metadata
Title
Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma
Association with severe myelotoxicity
Authors
Dr. Gil Bar-Sela
Diana Gaitini
Mariana Steiner
Nissim Haim
Publication date
01-09-2003
Publisher
Humana Press
Published in
Medical Oncology / Issue 3/2003
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1385/MO:20:3:291

Other articles of this Issue 3/2003

Medical Oncology 3/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine